Offres d'emploi

The Institute of NeuroPhysiopathology (INP) welcomes tenured researchers/lecturers, and junior researchers to lead or strengthen its research programmes

The Institute of NeuroPhysiopathology (INP) is a new laboratory of the CNRS/Aix-Marseille University created in 2018 that combines fundamental and translational research in a stimulating and friendly working environment (https://inp.univ-amu.fr). The INP is located on the Health Sciences Campus of La Timone, which is home to other leading neuroscience laboratories, bringing together more than 400 people covering a wide range of topics.

The INP seeks to attract the next generation of neuroscientists to explore new frontiers in human brain diseases (e.g., neurodegenerative diseases, brain cancer), the organisation of the neuronal cytoskeleton, cell reprogramming and disease modelling, brain-immune system crosstalk, neuron-glia interactions, blood brain barrier dysfunctions and the basis of cognition and circadian rhythms.

The INP is looking for two types of profiles:

1) Researchers and university lecturers holding a permanent position in France, interested in leading an independent research team or wishing to join existing teams.

2) Junior researchers looking for a permanent position in France to lead independent and innovative research programmes. We strongly encourage applications from candidates meeting the criteria to apply for ATIP-Avenir or European funded (e.g., ERC) programmes. We offer support and guidance in preparing applications for grants and permanent positions.

Candidates should send their application before 15 January 2021 in a single PDF file to the director of the laboratory, Dr Michel Khrestchatisky ( ) and to the deputy director, Dr Santiago Rivera ( ). Applications must include a CV and a cover letter describing current and future scientific endeavours.

The INP is a Laboratoire Commun de Recherche (Labcom) that offers an internationally competitive research environment in partnership with the biotechnology spin-off company Vect-Horus (https://www.vect-horus.com). The state-of-the-art technological facilities include super/high resolution and high throughput AI-based microscopy (STORM, SIM, SoRa, HCS), an iPS cell platform, and a biophysical platform specialized in molecular interactions (SPR, DSC, DSF, ITC, AUC and mass spectrometry). INP staff also have access to other cutting edge facilities on campus, including live 2-photon and electron microscopy, virus production and utilization facilities (A2-A3), functional imaging (MRI) and a brand new SPF rodent facility with space for surgery and animal behaviour studies. Hospital centres located near the campus facilitate interactions with clinicians, notably through the DHUNE federation of laboratories associated with the Centre of Excellence in Neurodegeneration (CoEN) (https://www.coen.org), of which the INP is a member.

The INP is a member of NeuroMarseille (https://neuro-marseille.org), a network of excellence that brings together scientists, clinicians and entrepreneurs, representing the 2nd largest neuroscience community in France. Within the framework of Aix-Marseille University, the INP is integrated into the new European University, CIVIS (https://civis.eu/fr), thus promoting scientific and training synergies in a rich and dynamic international environment. The INP is also part of the Institute of Oncology and Immunology and the Imaging Institute for Biology and Medicine of Marseille, which underlines its interdisciplinary character.

INP staff is actively involved in undergraduate teaching, as well as in the international PhD program through NeuroSchool, the Graduate School of Neuroscience (https://neuro-marseille.org/en/training/), which offers scholarships to foreign master and PhD students wishing to work in a NeuroMarseille laboratory.

Finally, the INP is located in the centre of Marseille, a few kilometres from the magnificent Parc National des Calanques and the scenic and cultural charms of Provence, a perfect complement to the dynamism of Marseille and its region as a place to live and do science.

 

  logo INP  logo AMU   logo CNRS    

 

Platform engineer : Conformational stability of proteins and protein ligands interactions

The Platform Interactome Timone of the Institute of Neurophysiopathology (INP) located at the Medical Faculty of AMU at Timone campus (Marseille) is seeking a dynamic and talented engineer with strong background in biophysical methods and protein biochemistry for participation in several interdisciplinary projects. Our unit uses biophysical techniques (Isothermal titration calorimetry, differential scanning calorimetry, differential scanning fluorimetry, dynamic light scattering, surface plasmon resonance etc.) to study the molecular mechanisms implicated in neurodegeneration and to develop new diagnostic methods.

The engineer will be involved in developing a novel universal diagnostic method based on denaturation profiles of human plasma samples that will be analyzed with the help of machine learning algorithms. Also, he/she will participate in the screening of a large library of inhibitors of protein-protein interactions to find new compounds that impact microtubular cytoskeleton.

The ideal candidate must have skills in biophysical methods, molecular biology, and biochemistry.
The position is opened for one year, renewable up to 3 years starting as early as January 2021. Net wage : 1500-1800 net
Address : Plateforme PINT, Institut de NeuroPhsyiopathology, UMR 7051, Faculté des Sciences Médicales et Paramédicales, 27 Bd Jean Moulin, 13005 Marseille
website : https://inp.univ-amu.fr/en/facilities/pint

Applicants must email a CV, a statement of interest and contact details for 2-3 references to francois.devred@univ-amu.fr

Relevant publications:

2020     An AI-powered blood test to detect cancer using nanoDSF

2020     In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor

2019     Plasmatic Signature of Disease by Differential Scanning Calorimetry (DSC)

2018     Differential scanning calorimetry of plasma in glioblastoma: toward a new prognostic/monitoring tool